CELL THERAPEUTICS, (CTIC) Stock Research Free Stock Rating

Company Profile

Cell Therapeutics, Inc. engages in the discovery, development, acquisition, and commercialization of drugs for the treatment of cancer. The company markets TRISENOX (arsenic trioxide) for the treatment of relapsed or refractory acute promyelocytic leukemia. Cell Therapeutics develops XYOTAX, paclitaxel linked to a polyglutamate polymer, which is used for the potential treatment of nonsmall cell lung cancer and ovarian cancer. It uses a biodegradable protein polymer to deliver the chemotherapy paclitaxel principally to tumor tissue. The company develops pixantrone, which is in clinical trials for the potential treatment of relapsed aggressive nonhodgkin’s lymphoma. It operates primarily in the United States and Italy. The company was co-founded by James A. Bianco, Louis A. Bianco, and Jack W. Singer in 1991. Cell Therapeutics is headquartered in Seattle, Washington.

Latest Headlines

Cell Therapeutics gets FDA priority review on drug (AP)

Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Date of April 2, 2009 (Business Wire)

Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides (PR Newswire)

FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review (PR Newswire)

Cell Therapeutics, Spectrum in deal to sell Zevalin (at bizjournals.com)

CELL THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Finan (EDGAR Online)

Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals (PR Newswire)

Spectrum and Cell Therapeutics to market Zevalin (AP)

Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug (PR Newswire)

Zacks #1 Rank Additions for Tuesday (Zacks.com)